IP Library Granted Patent US 7,563,864
Granted Patent B2
US 7,563,864 · App. 11/115,935 · Granted Jul 21, 2009

Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten

Assignees: Celiac Sprue Research Foundation; Universitetet I Oslo
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,563,864
App. No.
11/115,935
Granted
Jul 21, 2009
Kind
B2
Abstract

Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the proteolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.

Claims (7)

1. A purified gluten oligopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:32; SEQ ID NO:35; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:42; SEQ ID NO:44; SEQ ID NO:46; SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58; SEQ ID NO:59; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:64; SEQ ID NO:65; SEQ ID NO:66; SEQ ID NO:67; SEQ ID NO:68; SEQ ID NO:69; SEQ ID NO:72; SEQ ID NO:73; SEQ ID NO:74; SEQ ID NO:75; SEQ ID NO:76; SEQ ID NO:78; SEQ ID NO:80; SEQ ID NO:82; SEQ ID NO:83; and SEQ ID NO:84.

2. The oligopeptide of claim 1 , further comprising a label for chromogenic assays.

3. A purified gluten oligopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:46; SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58; SEQ ID NO:59; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:64; SEQ ID NO:65; SEQ ID NO:66; SEQ ID NO:67; SEQ ID NO:68; SEQ ID NO:69; SEQ ID NO:72; and SEQ ID NO:73.

4. The oligopeptide of claim 3 , further comprising a label for chromogenic assays.

5. A purified gluten oligopeptide having a sequence as selected from the group consisting of SEQ ID NO:32; SEQ ID NO:35; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:42; SEQ ID NO:44; SEQ ID NO:46; SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58; SEQ ID NO:59; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:64; SEQ ID NO:65; SEQ ID NO:66; SEQ ID NO:67; SEQ ID NO:68; SEQ ID NO:69; SEQ ID NO:72; SEQ ID NO:73; SEQ ID NO:74; SEQ ID NO:75; SEQ ID NO:76; SEQ ID NO:78; SEQ ID NO:80; SEQ ID NO:82; SEQ ID NO:83; and SEQ ID NO:84; which oligopeptide is covalently linked to a mammalian tTGase.

6. The oligopeptide of claim 5 , wherein said mammalian tTGase is selected from the group consisting of a human, bovine, equine, and porcine tTGase.

7. The oligopeptide of claim 6 , wherein said tTGase is covalently linked to said oligopeptide at a site of deamidation.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2016
From: ALVINE PHARMACEUTICALS, INC.
To: IMMUNOGENICS LLC
Reel/Frame 039060/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2009
From: CELIAC SPRUE RESEARCH FOUNDATION
To: ALVINE PHARMACEUTICALS, INC.
Reel/Frame 023332/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2007
From: MARTI, THOMAS
To: CELIAC SPRUE RESEARCH FOUNDATION
Reel/Frame 018868/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2006
From: MOLBERG, OYVIND; SOLLID, LUDVIG M.
To: UNIVERSITETET I OSLO
Reel/Frame 018669/0641 →
Continuity (2)
Provisional Application 6056568600 · Apr 26, 2004
Related Publication 20060286601A1 · Dec 21, 2006